2021
23 November 2021 – Entitlement Offer extension
15 November 2021 – Notice of Meeting & Proxy Form
5 November 2021 – Prospectus
5 November 2021 – Application for Quotation of Securities – Appendix 2A
5 November 2021 – Placement & Cleansing Notice
1 November 2021 – Investor Presentation 1 Nov 2021
1 November 2021 – Appendix 3B
1 November 2021 – Positive PDCO Opinion & $20M Placement
29 October 2021 – 2021 Annual Report
29 October 2021 – Appendix 4G & Governance Statement 2021
29 October 2021 – Quarterly Update and Apendix 4C
4 October 2021 – Antisense Therapeutics appoints new Non-Executive Director
30 September 2021 – Positive feedback received on Paediatric Investigation Plan
24 September 2021 – Statistically significant modulation in two DMD disease modifier proteins supports potential of ATL1102 in ambulant DMD and fibrotic conditions
20 September 2021 – New ATL1102 proteomics data to be presented in a Late Breaking News Abstract at the World Muscle Society 2021 Virtual Congress
25 August 2021 – Appendix 4E – Audited Financial Report Year Ended 30 June 2021
24 August 2021 – ANP to participate in PPMD development of new Community-Led Duchenne Guidance for FDA
12 August 2021 – ANP Updates on US Regulatory Plans for ATL1102 in DMD
28 July 2021 –Antisense Therapeutics transitions to new Board Chair
22 June 2021 – ATL1102 for DMD EMA PIP feedback and FDA regulatory progress
1 June 2021 – US FDA Feedback on Type C Meeting for ATL1102 in the US
26 May 2021 – Manufacture of ATL1102 clinical supplies for Phase IIb trial in DMD
28 April 2021 – Quarterly Report & Appendix 4C_March 2021
23 April 2021 – ATL1102 FDA Type C meeting
24 March 2021 – Director’s Initial Interest Notice
22 March 2021 – Appointment of new Non-Executive Director
19 March 2021 – Appendix 3G
4 March 2021 – FDA Rare Disease Day
26 February 2021 – Jett Foundation Rare Disease Day
25 February 2021 – Paediatric Investigation Plan for ATL1102 in DMD submitted to European Medicines Agency
24 February 2021 – Appointment of Joint Company Secretary
24 February 2021 – Half Yearly Report and Half Year Accounts
15 February 2021 – Antisense Therapeutics granted Type C meeting with US FDA for ATL1102 in DMD
28 January 2021 – Appendix 4C & Quarterly Report_31 Dec 20 QTR_Final
2020
European Commission grants Orphan Drug Designation for ATL1102 in DMD
ANP to present at Several Upcoming Virtual Conferences
ANP to present at Australian Equities Day
ANP Dual Lists on the Frankfurt Stock Exchange
ANP Share Purchase Plan Booklet
Notice of Annual General Meeting
Appendix 2A & Cleansing Notice
Antisense Therapeutics Limited raises A$7.3 million in oversubscribed Placement
Antisense Therapeutics Limited raises A$7.3 million in oversubscribed Placement
ANP to apply for dual listing on Frankfurt Stock Exchange
ANP receives US FDA Orphan Drug Designation for ATL1102 for the treatment of DMD
Quarterly Report & Appendix 4C
US FDA Grants Rare Pediatric Disease Designation to ATL1102 for the treatment of DMD
ANP Submits EMA Orphan Drug Application for ATL1102 in DMD
Appendix 4E & Full Year Statutory Accounts
ANP Submits US FDA Orphan Drug Application for ATL1102 in DMD
Quarterly Update & Appendix 4C
EMA DMD Scientific Advice and Regulatory Process Update
ANP to Participate at 2020 PPMD Virtual Annual Conference
Sharecafe Small Cap “Hidden Gems” Webinar Presentation
Antisense Therapeutics to Present at Webinar Hosted by Parent Project Muscular Dystrophy in the US
Poster Presentation on the Muscular Dystrophy Association Virtual Conference 2020 website
Antisense to Present at NWR Virtual Health Conference
Quarterly Update and Appendix 4C
ATL1102 Phase II DMD trial database lock and final results on track
ATL1102 Phase II DMD trial data to be presented at Duchenne ACTT Now Conference
App 4D – Half yearly report and half yearly accounts
Appointment of US-based Consultant Medical Director
Results in DMD unlock value creation potential of ATL1102
Appendix 4C – Quarterly Report
Appointment of new Non-Executive Director
Presentation for SACHS 3rd Neuroscience Innovation Forum
2019
Change of Directors Interest Notice (RM, MD, GM, GP, WG)
Change of Directors Interest Notice (WG)
Change of Directors Interest Notice (RM)
Change of Directors Interest Notice (RM)
Change of Directors Interest Notice (MD)
Change of Directors Interest Notice (GM)
Positive Results reaffirm plans to advance ATL1102 to Phase IIb
Underwriting of Listed Options
Change of Directors Interest Notice (RM)
AGM Presentation December 2019
Change of Directors Interest Notice (RM)
Dosing Completed in ATL1102 Phase II DMD trial
Additional ATL1102 trial data presented at DMD UK conference
Antisense Therapeutics Listed Option Exercise
Notice of Annual General Meeting/Proxy Form incl. Annual Report
ANP – Appendix 3B – 29 Oct 2019
Neuromuscular Drug Development Summit Poster Presentation
ANP – Appendix 4C – 30 Sept 19_final
ANP to present at Neuromuscular Drug Development Summit in USA
ANP – Appendix 3B – 04 Oct 2019
Positive Preliminary results from ATL1102 for DMD Phase II trial
ATL1102 for DMD commencement of European regulatory interactions
ATL1102 Phase II clinical trial in DMD update
Conference Presentation June 2019
ATL1102 Phase II clinical trial in DMD final enrolment
ATL1102 Phase II clinical trial in DMD update
Placement to Accelerate Development of ATL1102 in DMD
ASX 19_30 Jan_ANP – Appendix 4C – 31 Dec 18
ASX 19_23 Jan_Updated Company Presentation
ASX 19_ 18 January ATL1102 Phase II clinical trial in DMD update_Final